Wall Street brokerages expect Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) to report $1.06 billion in sales for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Alexion Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.13 billion and the lowest estimate coming in at $1.04 billion. Alexion Pharmaceuticals posted sales of $909.70 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 16.5%. The company is scheduled to issue its next earnings results on Thursday, February 14th.
On average, analysts expect that Alexion Pharmaceuticals will report full-year sales of $4.07 billion for the current fiscal year, with estimates ranging from $4.04 billion to $4.13 billion. For the next financial year, analysts anticipate that the firm will report sales of $4.76 billion, with estimates ranging from $4.50 billion to $4.92 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.74 by $0.28. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.02 billion. Alexion Pharmaceuticals had a net margin of 3.90% and a return on equity of 16.60%. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.44 earnings per share.
A number of analysts have issued reports on the stock. ValuEngine upgraded shares of Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Monday, September 24th. BidaskClub upgraded shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Leerink Swann set a $181.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, October 24th. Credit Suisse Group set a $156.00 price target on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, September 25th. Finally, Stifel Nicolaus boosted their price target on shares of Alexion Pharmaceuticals from $130.00 to $136.00 and gave the stock a “hold” rating in a research note on Tuesday, September 25th. Three analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $161.50.
NASDAQ:ALXN traded down $5.44 on Monday, reaching $115.60. 1,229,654 shares of the company’s stock were exchanged, compared to its average volume of 1,105,094. The company has a debt-to-equity ratio of 0.32, a current ratio of 3.16 and a quick ratio of 2.74. The firm has a market capitalization of $27.00 billion, a PE ratio of 22.40, a price-to-earnings-growth ratio of 1.04 and a beta of 1.02. Alexion Pharmaceuticals has a 52-week low of $102.10 and a 52-week high of $140.77.
In related news, EVP Indrani Lall Franchini sold 2,605 shares of the company’s stock in a transaction that occurred on Wednesday, November 28th. The shares were sold at an average price of $118.13, for a total transaction of $307,728.65. Following the sale, the executive vice president now directly owns 29,304 shares in the company, valued at $3,461,681.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 4.35% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. First Hawaiian Bank purchased a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $102,000. Advisory Services Network LLC increased its stake in Alexion Pharmaceuticals by 145.3% in the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 523 shares during the last quarter. Columbia Asset Management purchased a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $138,000. Checchi Capital Advisers LLC purchased a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $204,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Alexion Pharmaceuticals in the third quarter valued at approximately $205,000. Hedge funds and other institutional investors own 93.33% of the company’s stock.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.